The study aimed to assess the effect of localized disasters on health plan quality performance scores, according to lead investigator Maria DeYoreo, PhD, of RAND Corporation.
In an interview with Maria DeYoreo, PhD, senior statistician at the RAND Corporation and co-director of the RAND Center for Causal Inference, she shares the inspiration behind her study published in the February 2025 issue of The American Journal of Managed Care® titled, "Do Localized Disasters Impact Clinical Measures of Health Care Quality?"
DeYoreo also discusses the key concerns for performance measurement programs when assessing provider quality in disaster-affected areas and how CMS has addressed these in the Medicare Advantage Star Ratings program.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
What are the key concerns for performance measurement programs when assessing provider quality in disaster-affected areas? How has CMS addressed these concerns in the Medicare Advantage Star Ratings program?
Well, the primary concern is that health plans or contracts that operate in areas that were impacted by localized disasters, such as fires, floods, hurricanes, or earthquakes, may see lower performance scores. For example, they may have lower rates of breast cancer screening or receive worse ratings of patient experience measures as a consequence of the disaster. It might be unfair to compare them to contracts that were not affected by a disaster.
CMS has addressed these concerns with something called the disaster policy in the star ratings, which allows contracts that had a meaningful or substantial percent of enrollees residing in disaster-affected areas to receive the higher of their current year–measure star rating or their prior year–measure star rating and scores. The purpose of this policy is to avoid unfairly penalizing disaster-affected contracts.
What was the objective of your study? Why did you decide to investigate this?
We wanted to determine the effect of localized disasters on health plans' quality performance scores using a variety of clinical and patient experience measures. We investigated this because we wanted to know whether disasters meaningfully impact performance in a negative way and which measures are affected by disasters and which aren't.
Ultimately, this has implications for performance measurement programs in terms of whether quality of care measure performance data can continue to be used for public reporting or payment purposes.
How did you define and measure "disaster exposure" for Medicare Advantage contracts?
We defined disaster exposure as the percentage of MA [Medicare Advantage] contract enrollees or beneficiaries who resided in disaster-affected areas during the performance year or the performance period.
The disaster-affected areas were FEMA [Federal Emergency Management Agency]–designated individual assistance counties where the HHS secretary declared a public health emergency.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora
March 26th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
High Drug Costs, PBM Reform, and Access Challenges Take Center Stage at AMCP 2025
March 25th 2025As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, the upcoming AMCP annual meeting will provide critical insights into legislative impacts, drug affordability, formulary design, and emerging treatment trends.
Read More